The number of participants who completed treatment at weeks 8 and 12 were included in the analysis for those weeks. CIPN indicates chemotherapy-induced peripheral neuropathy.
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bao T, Patil S, Chen C, et al. Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(3):e200681. doi:10.1001/jamanetworkopen.2020.0681
Chemotherapy-induced peripheral neuropathy (CIPN) is the most common and debilitating long-term adverse effect of neurotoxic chemotherapy that significantly worsens cancer survivors’ quality of life. Well-tolerated, evidence-based interventions for CIPN are needed.1
This pilot randomized clinical trial compared the effect of 8 weeks of real acupuncture vs sham acupuncture or usual care to treat CIPN. The trial protocol (Supplement 1) was approved by the institutional review board of Memorial Sloan Kettering Cancer Center and follows the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline (Figure). Written informed consent was obtained from all study participants. Patients with solid tumors with persistent moderate to severe CIPN (symptoms of numbness, tingling, or pain rated ≥4 on a numeric rating scale [NRS]) who had completed 3 or more months of chemotherapy prior to study enrollment and were not taking stable neuropathic medication were eligible. Patients were allocated 1:1:1 to real acupuncture, sham acupuncture, or usual care through computer-generated randomization conducted by the Clinical Research Database in randomly permuted blocks.
The real acupuncture group received ear and body acupuncture at Shen Men, point zero, and a third electrodermal active point,2 and bilateral body: LI-4, PC-6, SI-3, LR-3, GB-42, ST-40, Bafeng 2, and Bafeng 3. Electrical acupuncture was also applied bilaterally from LR-3 (negative) to GB-42 (positive) at 2 to 5 Hz for 20 minutes. The sham acupuncture group received a noninsertion procedure on nonacupoints. The usual care group did not receive any interventions throughout the study period. Investigators, study coordinators, and the statistician were blinded to the treatment assignments.
The primary end point was CIPN symptom severity measured by NRS (11-point scale; 0 = no symptoms and 10 = worst symptom imaginable) at week 8. In prior studies, the NRS had high reliability and validity.3,4 We targeted a sample size of 25 participants in each group. This sample size allowed us to estimate the upper bound of a 1-sided 90% confidence interval for the treatment effect on outcome (eg, sham acupuncture vs real acupuncture or usual care vs real acupuncture) to 0.35-unit SDs. Mixed-effects models with an interaction term between group and assessment time (up to 8 weeks) were fit to examine whether temporal changes in a measure differed by group. The threshold for statistical significance was set at 2-sided P < .05.
From July 2017 to June 2018, we enrolled 75 patients with solid tumors with moderate to severe CIPN (median [interquartile range] age, 59.7 [36.3-85.9] years; 60 [80%] female; 55 [73%] white; 40 [53%] with breast cancer and 12 [16%] with colorectal cancer). In all, 24 patients were randomized to real acupuncture, 23 to sham acupuncture, and 21 to usual care. Compared with usual care, NRS-measured pain, tingling, and numbness significantly decreased in real acupuncture at week 8 (Table). From baseline to week 8, mean absolute reduction in CIPN pain was greatest in real acupuncture (−1.75 [95% CI, −2.69 to −0.81]) and least in usual care (−0.19 [95% CI, −1.13 to 0.75]) (Table). At the 8-week assessment, sham acupuncture had a reduction of −0.91 (95% CI, −2.0 to 0.18). At the longer 12-week follow-up, real acupuncture had a mean absolute reduction in NRS-measured pain of −1.74 (95% CI, −2.6 to −0.83) from baseline, while sham treatment had a reduction of −0.34 (−1.3 to 0.61). Adverse events were few and mild.
We found therapeutic benefit of real acupuncture for neuropathic pain that is consistent with previous pilot acupuncture CIPN trials.5,6 Distinctively, our study is the first, to our knowledge, to incorporate a sham treatment and a nontreatment control to evaluate the efficacy of acupuncture for CIPN. The addition of a sham acupuncture control in an acupuncture clinical trial is difficult owing to the challenge of incorporating a truly inert placebo. In addition, a sham control limits the ability of a small effect size to elucidate a true difference between real and sham acupuncture. Not only did our study demonstrate the feasibility of conducting a sham-controlled acupuncture trial, it generated sufficient pilot data to inform a definitive sham-controlled efficacy trial. Our trial is limited by its small sample size, single center, and short-term follow-up.
In conclusion, compared with usual care, acupuncture resulted in significant improvement in CIPN symptoms. The effect size observed between real and sham control will inform a rigorous and adequately powered trial to establish the efficacy of acupuncture for CIPN.
Accepted for Publication: January 14, 2020.
Published: March 11, 2020. doi:10.1001/jamanetworkopen.2020.0681
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Bao T et al. JAMA Network Open.
Corresponding Author: Ting Bao, MD, DABMA, MS, Bendheim Integrative Medicine Center, 1429 First Ave, New York, NY 10021 (firstname.lastname@example.org).
Author Contributions: Dr Bao had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Bao was the principal investigator.
Concept and design: Bao, Mao.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bao, Patil, Chen, Zhi, Piulson.
Critical revision of the manuscript for important intellectual content: Bao, Patil, Zhi, Li, Mao.
Statistical analysis: Bao, Patil, Li, Mao.
Obtained funding: Bao.
Administrative, technical, or material support: Bao, Piulson.
Supervision: Bao, Piulson, Mao.
Conflict of Interest Disclosures: Dr Bao reported receiving grants from the National Institutes of Health/National Cancer Institute during the conduct of the study. Dr Mao reported receiving grants from Tibet Cheezheng Tibetan Medicine Co, Ltd and Zhongke Health International LLC outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported in part by a National Institutes of Health/National Cancer Institute Cancer Center grant (P30 CA008748), the Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center, and the Frueauff Foundation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Trial Registration: ClinicalTrials.gov Identifier: NCT03183037
Additional Contributions: Yi Chan, Jonathan Siman, Lily Zhang, and Matthew Weitzman (Memorial Sloan Kettering Cancer Center Integrative Medicine Service) provided the acupuncture intervention for this study; Patricia Chen, BA (Memorial Sloan Kettering Cancer Center Integrative Medicine Service), assisted in conducting this study; and Victoria Blinder, MD (Memorial Sloan Kettering Cancer Center Breast Medicine Service), Mark Robson, MD (Memorial Sloan Kettering Cancer Center Breast Medicine Service), Andrew Seidman, MD (Memorial Sloan Kettering Cancer Center Breast Medicine Service), Linda Vahdat, MD (Norwalk Hospital), and Steven Sugarman, MD (Memorial Sloan Kettering Commack), assisted with recruiting patients. None of these individuals were compensated for their contributions. We thank all the cancer survivors in this study for their participation.
Data Sharing Statement: See Supplement 2.
Create a personal account or sign in to: